A Phase 1 interventional study of Ivermectin Lotion, 0.5% and SKLICE (ivermectin) Lotion, 0.5% in Lice; Head Lice, sponsored by Taro Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-18.
Sponsored by Taro Pharmaceuticals USA (part of Sun Pharmaceutical Industries Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Lice Infestations with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Lice Infestations · United States.
Among the 25 studies in Lice Infestations with a site in United States, this one is the 3rd largest by enrollment, is the only one that started in 2017, is one of 3 in phase 1, and was the 21st registered.
43 studies on the registry are indexed under Lice Infestations; 4 are open to participants now.
Browse Lice Infestations studies →1 of the 25 studies in Lice Infestations with a site in United States is open now. Recruiting first, the newest first:
Oystershell NV · Sites in United States
Ages 1+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Lice Infestations studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 7 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 413 is above the median of 105 across 42 interventional studies indexed under Lice Infestations.
Median enrollment 98 across the 25 interventional studies. Of the 23 that completed or were terminated, 13 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 25 have an industry lead sponsor. The 9 most frequent:
This study is registered under Taro Pharmaceuticals USA, one of the names counted as Sun Pharmaceutical Industries Limited. Under that name alone:
Taro Pharmaceuticals USA is the lead sponsor of 71 studies on the registry; none are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 1 (5%) have results posted.
Sun Pharmaceutical Industries Limited has 7 studies filed under Lice Infestations — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Lice Infestations with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Multi-Center, Double-Blind, Randomized, Placebo controlled, Parallel-group study, comparing Ivermectin Lotion, 0.5%
A Multi-Center, Double-Blind, Randomized, Placebo controlled, Parallel-group study, comparing Ivermectin Lotion, 0.5% to Sklice (Ivermectin) Lotion, 0.5% and both active treatment to a placebo control in the treatment of subjects with active infestation with head lice and their Ova
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One 10 minute application, under at-home use conditions
Drug: Ivermectin Lotion, 0.5%
One 10 minute application, under at-home use conditions
Drug: SKLICE (ivermectin) Lotion, 0.5%
One 10 minute application, under at-home use conditions
Drug: Vehicle of the Test product
Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
Also known as: ivermectin
SKLICE (ivermectin) Lotion, 0.5% (Arbor Pharmaceuticals, LLC)
Also known as: ivermectin
Vehicle for Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
Also known as: placebo
Demonstration of Bioequivalence in proportion of index subjects who are lice free
Demonstration of Bioequivalence in proportion of index subjects who are lice free
Time frame: Day 15 (14 days after application of study treatment)
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2017 to primary completion in Jun 2017, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivermectin